Drug intelligence / Profile preview

SSKI-101

Development stage: Unknown
Lead developer: SKYDD Biotechnology
Modality: Antibody-Based Therapeutics
Administration: Intranasal, Oral

Overview

SSKI-101 is an investigational anti-SARS-CoV-2 immunoglobulin Y (IgY) nasal and oral spray being developed by SKYDD Biotechnology for the prevention of COVID-19. As a passive immunization agent, it consists of avian-derived antibodies typically harvested from the egg yolks of immunized hens. The product is designed to provide local mucosal protection by neutralizing the SARS-CoV-2 virus, specifically targeting the spike protein to prevent viral entry into host cells. SSKI-101 is administered four times daily and is currently being evaluated in Phase 2/3 clinical trials to assess its safety, tolerability, and efficacy in preventing COVID-19 infection in healthy adults.

Other names: anti-SARS-CoV-2 IgYanti-SARS-CoV2 IgYanti-SARS-CoV 2 IgYimmunoglobulin Y

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on SSKI-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SSKI-101.

Explore the full profile